Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing ...

About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

The arc of biotechnology is one of breakthroughs and struggles, writes Tim Hunt, CEO of the Alliance for Regenerative ...

B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Panelists discuss how ciltacabtagene autoleucel (cilta-cel) demonstrates superior outcomes compared to real-world physician’s ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Synthetic Biology is advancing the use of microorganisms as cancer therapies, with scientists engineering bacteria to boost antitumor immunity and deliver ...

Use of DYNE-101 is leading to improvements in muscle, and specifically finger, function in myotonic dystrophy type 1 patients ...

After October 7, Israel sees a mental health tech boom: 117 startups tackling trauma, resilience with AI, self-care, and ...

NYU scientists have discovered that cancer cells work together to withstand challenging conditions, revealing new ...

Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...